Both glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose cotransporter 2 (SGLT2) inhibitors have demonstrated improvements in cardiorenal outcomes in several cardiovascular outcome trials (CVOTs), especially in patients with type 2 diabetes (T2DM) who have a high risk of CVD [11, 12]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.